
NASPGHAN ALERT: Guidance for Flovent HFA Upcoming Discontinuation Used For The Treatment of Eosinophilic Esophagitis
Please see the following alert from the EGID Special Interest Group. Situation: Brand name Flovent HFA will no longer be manufactured after December 31, 2023. Background: • Flovent HFA is a commonly utilized swallowed topical steroid treatment for patients with eosinophilic esophagitis (EoE). It works by the patient swallowing the aerosolized medication dispensed by a
read more